Skip to main content

Table 4 Summary of case reports on the use of sugammadex in patients with neuropathies (n = 2)

From: Use of sugammadex in patients with neuromuscular disorders: a systematic review of case reports

Author/year

Country

Patient characteristics

Disease

Type of surgery; Duration of surgery

Anesthetic agents

NMBA

NM monitoring

Dose of sugammadex & results of NM monitor

Postoperative course

Weekes et al., 2010

Ireland

38/F; 70 kg

Idiopathic transverse myelitis

Elective cesarean section; 60 min

Thiopentone and rapid sequence induction followed by maintenance with morphine, sevoflurane/oxygen/nitrous oxide; propofol infusion during delayed extubation

Rocuronium 1.2 mg/kg

Qualitative neuromuscular monitoring

Initial neostigmine 5 mg (0.07 mg/kg) & glycopyrollate 1 mg; Pre reversal TOF: four weak TOF twitchesa; Post reversal TOF: 4 weak twitches (for more than 1 h). Sugammadex 4 mg/kg administered (delayed administration because of unavailability) followed by all the clinical signs of adequate recovery in 2 min

Uneventful extubation and recovery

Staikou and Rekatsina, 2017

Greece

31/F; 62 kg; 164 cm; BMI: 23.1 kg/m2

Multiple sclerosis

Myomectomy; 65 min

Benzodiazepine premedication. Propofol, fentanyl induction followed by maintenance with fentanyl boluses, sevoflurane, nitrous oxide/oxygen

Rocuronium 1 mg/kg for intubation with no further doses

Neuromuscular module of S/5 anaesthesia monitor

Sugammadex 2 mg/kg; Pre reversal TOF count: 3; Post reversal TOF ratio: 0.9 (0.75 min)

Uneventful extubation and recovery.

  1. TOF Train of four; PTC Post tetanic count; N.R. Not reported; NMBA Neuromuscular blocking agent; NM Neuromuscular
  2. aUsing facial nerve